Deal Tracker · Countries

Kuwait pharma deals

10 pharma deals involving Kuwait — companies based there or deals covering the market — tracked by EPT: distribution, licensing & M&A. Most active: Al Wataniya Aldawliya, Alfasigma, Arcera Life Sciences & Daewoong Pharmaceutical. Latest: Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).

10
deals tracked
8
announced in 2026
$743m
disclosed value (3 deals)
40%
distribution, the top deal type
  • EPT has tracked 10 Kuwait pharma deals (2022–2026), 8 of them announced in 2026.
  • The most common structures are distribution (40%), licensing (20%) & m&a (20%).
  • Values were disclosed for 3 of 10 deals, totalling $743m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).

Countries involved

Oman (7) · Saudi Arabia (7) · UAE (7) · Bahrain (6) · Egypt (4) · Qatar (4)

Largest disclosed deals

Questions

How many Kuwait pharma deals has EPT tracked?
10 as of 12 Nov 2026, covering 2022–2026; 8 were announced in 2026. The most recent is Emmaus Life Sciences → Al Wataniya Aldawliya (Distribution, 12 Nov 2026).
What types of Kuwait pharma deals are most common?
Distribution: 4 (40%); Licensing: 2 (20%); M&A / Acquisition: 2 (20%); Partnership / Collaboration: 2 (20%).
What is the largest disclosed Kuwait pharma deal?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)